{"id":852727,"date":"2025-05-20T08:09:27","date_gmt":"2025-05-20T12:09:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/"},"modified":"2025-05-20T08:09:27","modified_gmt":"2025-05-20T12:09:27","slug":"philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/","title":{"rendered":"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures"},"content":{"rendered":"<div class=\"mw_release\">\n<p>May 20, 2025<\/p>\n<ul>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <em>Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation<\/em>\n        <\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <em>824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US<\/em>\n        <\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <em>Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance.<\/em>\n        <\/li>\n<\/ul>\n<p>\n        <strong>Amsterdam, the Netherlands \u2013<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fq-tVGVdtVUlq7LqCnDuAZz2t0yHMqj2WHS_sNirGg0ZzPi67S6Xh6qWuePY3BnlX14b6uR-Fo5Mi64i3tnvDz02w9im-m_U2x73u26nKsM=\" rel=\"nofollow\" target=\"_blank\">Royal Philips<\/a> (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YljNghT0xcyqh17EA5bPebv0_IPfeENSuy909h7hi2vElwe6vs_YJ6rxIsJ26cSlMllIYsIwgVZxXr2QrwN6vKw86HXujsF9mk1_mTYVecI=\" rel=\"nofollow\" target=\"_blank\">RADIQAL<\/a> (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark.<\/p>\n<p>\u201cThe ability to reduce radiation exposure without compromising procedural performance is a key priority in interventional cardiology,\u201d said Dr. Javier Escaned, Professor of Cardiology at Hospital Cl\u00ednico San Carlos and principal investigator. \u201cIt is also important to achieve high-quality angiograms when using diluted contrast media as part of ultra-low contrast procedures. RADIQAL is designed to generate robust, real-world evidence on whether Philips\u2019 new ultra-low X-ray dose technology can reduce radiation exposure for patients and staff without affecting the quality of coronary procedures.\u201d<\/p>\n<p>Coronary artery disease (CAD) is the most frequent type of heart disease affecting millions of people worldwide. It is caused by chronic inflammation of the coronary arteries, which may lead to a gradual obstruction or sudden occlusion of blood flow to the heart muscle. Percutaneous coronary intervention (PCI) is a widely used image-guided, minimally invasive procedure to open blocked coronary arteries and treat CAD. Philips Azurion is an image-guided therapy system which is used for live X-ray imaging during such procedures.<\/p>\n<p>The RADIQAL trial evaluates radiation exposure, image quality and procedural performance between Philips\u2019 new ultra-low dose technology and existing ClarityIQ technology, both integrated into the Azurion image-guided therapy system. The new technology features an ultra-low dose protocol for coronary procedures, reducing X-ray exposure by 50% compared to even the lowest setting currently available on our Azurion systems with ClarityIQ.\u00a0This technology has obtained CE marking and as such is cleared under the EU MDR regulatory framework*.<\/p>\n<p>\u201cReducing radiation exposure while maintaining or improving image-quality is one of the most important innovation goals in interventional cardiology,\u201d said Dr. Darshan Doshi, Head of Medical &amp; Clinical at Philips Image-Guided Therapy Devices and Interventional Cardiologist at the Massachusetts General Hospital in Boston, USA. \u201cInterventional cardiologists rely on low-dose, high-quality imaging for confident decision-making throughout multiple procedures each day. Also for patients, especially those with high BMI or with complex conditions requiring repeat interventions, minimizing radiation exposure is increasingly critical.\u201d<\/p>\n<p>*\u00a0 Not cleared as a medical device in FDA-regulated countries. Enrollment in the US has not started.<\/p>\n<p>\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<p>Joost Maltha<br \/>Philips Global External Relations <br \/>Tel.: +31 6 10 55 8116<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZqWIm0rsj1I_i_hRpXT3RGLJGC-lAkLkP6RNxjo7t0JNATxeGKleBJEym3TYGfJlD-rTU9MdNVSOw348dSBG6x4SGCaO1U9Xy-wn67SSyOOK-44baNnJtz1RGBShU5nA\" rel=\"nofollow\" target=\"_blank\">joost.maltha@philips.com<\/a><\/p>\n<p>\n        <strong><br \/>\n          <strong>About Royal Philips<\/strong><br \/>\n        <\/strong>\n      <\/p>\n<p>Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people\u2019s health and well-being through meaningful innovation. Philips\u2019 patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.<\/p>\n<p>Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FEvbHOYON0-kPZvkZqjok5MoIMWQQBPt5PgCO1XO-sh8vix7VVch6kbJKoYlVPouBVieaV9r57qHjuX8UPIr50aeogYUzEVKrZpq4sWVshM9L5h8HGjNX5F78I5UvV_H\" rel=\"nofollow\" target=\"_blank\">www.philips.com\/newscenter<\/a>.<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/8c64d600-8992-4d15-b159-890bdae847c1\">Philips RADIQAL trial<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZTdjM2U3OWYtMDVlYS00MWNiLTkwZWQtYTVkNWY5MTA5ZGVhLTEwMTQzNzUtMjAyNS0wNS0yMC1lbg==\/tiny\/Philips-International-B-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation 824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands \u2013 Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark. \u201cThe ability to reduce radiation exposure without compromising procedural &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-852727","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation 824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands \u2013 Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark. \u201cThe ability to reduce radiation exposure without compromising procedural &hellip; Continue reading &quot;Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T12:09:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures\",\"datePublished\":\"2025-05-20T12:09:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/\"},\"wordCount\":593,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/\",\"name\":\"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==\",\"datePublished\":\"2025-05-20T12:09:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/","og_locale":"en_US","og_type":"article","og_title":"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures - Market Newsdesk","og_description":"May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation 824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands \u2013 Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark. \u201cThe ability to reduce radiation exposure without compromising procedural &hellip; Continue reading \"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-20T12:09:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures","datePublished":"2025-05-20T12:09:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/"},"wordCount":593,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/","name":"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==","datePublished":"2025-05-20T12:09:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5Nzc3OCM0MDIxNDQ3OTMjMjAwMjgwMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philips-launches-radiqal-study-to-generate-real-world-evidence-for-new-ultra-low-x-ray-dose-technology-in-coronary-procedures\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=852727"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852727\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=852727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=852727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=852727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}